Status
Conditions
Treatments
About
This study is an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.
Full description
This is a primary data collection-based special drug-use surveillance to be conducted in accordance with the GPSP ordinance.
Observational period will last 24 months from the start of treatment with Kesimpta.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients must provide written consent to cooperate in this study before the start of treatment with Kesimpta
Patients using Kesimpta for the first time for the following indication Indication: prevention of relapses and and prevention of physical disability progression in the following patients
Exclusion criteria
367 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal